Adverse effects · high‐grade glioma
1 finding from 1 review
Progression‐free survival · high‐grade glioma
1 finding from 1 review
Quality of life · high‐grade glioma
1 finding from 1 review
Overall survival for subgroup age 60 years and older glioblastoma · high‐grade glioma
Hypofractionated radiotherapy showed no clear difference in overall survival for subgroup aged ≥ 60 years glioblastoma compared with daily conventionally fractionated radiotherapy (high certainty).
1 finding from 1 review
Overall survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Grade ≥ 3 diarrhoea · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 hypokalaemia · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).
1 finding from 1 review
Quality of life · treatment of relapsed epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DepressionProfile of Moods Scale (depression subscale) and Hospital Anxiety and Depression Scale · patients with improving psychological and physical outcomes in cancer patients
1 finding from 1 review
StressSymptom Checklist_90_Revised and Perceived Stress Scale · patients with improving psychological and physical outcomes in cancer patients
1 finding from 1 review
Fatigue · patients with improving psychological and physical outcomes in cancer patients
1 finding from 1 review
Body image · patients with improving psychological and physical outcomes in cancer patients
1 finding from 1 review
Anxiety · patients with improving psychological and physical outcomes in cancer patients
1 finding from 1 review
CI: Confidence interval · patients with improving psychological and physical outcomes in cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.07 [0.91, 1.25]
4 studies · 541 participants
Moderate
RR 1.06 [0.97, 1.17]
3 studies · 761 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate